O
PCVX icon

OrbiMed’s Vaxcyte PCVX Stock Holding History

OrbiMed’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-387,000
Closed -$44.2M – 132
2024
Q3 		$44.2M Sell
387,000
-408,900
-51% -$36.9M 0.8% 39
2024
Q2 		$60.1M Sell
795,900
-270,231
-25% -$18.4M 1.19% 25
2024
Q1 		$72.8M Sell
1,066,131
-86,960
-8% -$6.02M 1.33% 26
2023
Q4 		$72.4M Buy
1,153,091
+145,943
+14% +$7.58M 1.45% 23
2023
Q3 		$51.3M Hold
1,007,148
– – 1.09% 31
2023
Q2 		$50.3M Buy
1,007,148
+277,709
+38% +$13.2M 0.91% 40
2023
Q1 		$27.3M Sell
729,439
-553,687
-43% -$23.5M 0.54% 57
2022
Q4 		$61.5M Buy
1,283,126
+565,226
+79% +$22.2M 1.18% 29
2022
Q3 		$17.2K Sell
717,900
-795,759
-53% -$20.2M 0.32% 69
2022
Q2 		$32.9K Hold
1,513,659
– – 0.6% 53
2022
Q1 		$36.6M Buy
1,513,659
+416,959
+38% +$9.11M 0.59% 49
2021
Q4 		$26.1M Buy
1,096,700
+62,035
+6% +$1.44M 0.34% 70
2021
Q3 		$26.2M Buy
1,034,665
+89,265
+9% +$2.16M 0.29% 84
2021
Q2 		$21.3M Buy
945,400
+296,626
+46% +$6.07M 0.22% 97
2021
Q1 		$12.8M Buy
648,774
+18,514
+3% +$466K 0.12% 114
2020
Q4 		$16.7M Sell
630,260
-10,500
-2% -$390K 0.15% 107
2020
Q3 		$31.6M Sell
640,760
-209,240
-25% -$8.33M 0.4% 68
2020
Q2 		$26.9M Buy
+850,000
New +$27.3M 0.38% 66

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's PCVX Position: Q4 2024 in Review

OrbiMed sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 387,000 shares — an estimated $44.2M sold.

OrbiMed first reported a position in PCVX in Q2 2020 and held it in 18 quarters. The position peaked at $72.8M in Q1 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • OrbiMed reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • OrbiMed sold 387,000 Vaxcyte shares in Q4 2024, an estimated $44.2M.
  • OrbiMed first reported a position in Vaxcyte in Q2 2020 and held it in 18 quarters.
  • OrbiMed's Vaxcyte position peaked at $72.8M in Q1 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.